<?xml version='1.0' encoding='utf-8'?>
<document id="24820076"><sentence text="Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6."><entity charOffset="0-9" id="DDI-PubMed.24820076.s1.e0" text="Isoniazid" /><entity charOffset="71-80" id="DDI-PubMed.24820076.s1.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.24820076.s1.e0" e2="DDI-PubMed.24820076.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24820076.s1.e0" e2="DDI-PubMed.24820076.s1.e1" /></sentence><sentence text="Efavirenz is commonly used to treat patients coinfected with human immunodeficiency virus and tuberculosis"><entity charOffset="0-9" id="DDI-PubMed.24820076.s2.e0" text="Efavirenz" /></sentence><sentence text=" Previous clinical studies have observed paradoxically elevated efavirenz plasma concentrations in patients with the CYP2B6*6/*6 genotype (but not the CYP2B6*1/*1 genotype) during coadministration with the commonly used four-drug antituberculosis therapy"><entity charOffset="64-73" id="DDI-PubMed.24820076.s3.e0" text="efavirenz" /></sentence><sentence text=" This study sought to elucidate the mechanism underlying this genotype-dependent drug-drug interaction" /><sentence text=" In vitro studies were conducted to determine whether one or more of the antituberculosis drugs (rifampin, isoniazid, pyrazinamide, or ethambutol) potently inhibit efavirenz 8-hydroxylation by CYP2B6 or efavirenz 7-hydroxylation by CYP2A6, the main mechanisms of efavirenz clearance"><entity charOffset="97-105" id="DDI-PubMed.24820076.s5.e0" text="rifampin" /><entity charOffset="107-116" id="DDI-PubMed.24820076.s5.e1" text="isoniazid" /><entity charOffset="118-130" id="DDI-PubMed.24820076.s5.e2" text="pyrazinamide" /><entity charOffset="135-145" id="DDI-PubMed.24820076.s5.e3" text="ethambutol" /><entity charOffset="164-173" id="DDI-PubMed.24820076.s5.e4" text="efavirenz" /><entity charOffset="203-212" id="DDI-PubMed.24820076.s5.e5" text="efavirenz" /><entity charOffset="263-272" id="DDI-PubMed.24820076.s5.e6" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e0" e2="DDI-PubMed.24820076.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e0" e2="DDI-PubMed.24820076.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e0" e2="DDI-PubMed.24820076.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e0" e2="DDI-PubMed.24820076.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e0" e2="DDI-PubMed.24820076.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e0" e2="DDI-PubMed.24820076.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e0" e2="DDI-PubMed.24820076.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e1" e2="DDI-PubMed.24820076.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e1" e2="DDI-PubMed.24820076.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e1" e2="DDI-PubMed.24820076.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e1" e2="DDI-PubMed.24820076.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e1" e2="DDI-PubMed.24820076.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e1" e2="DDI-PubMed.24820076.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e2" e2="DDI-PubMed.24820076.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e2" e2="DDI-PubMed.24820076.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e2" e2="DDI-PubMed.24820076.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e2" e2="DDI-PubMed.24820076.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e2" e2="DDI-PubMed.24820076.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e3" e2="DDI-PubMed.24820076.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e3" e2="DDI-PubMed.24820076.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e3" e2="DDI-PubMed.24820076.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e3" e2="DDI-PubMed.24820076.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e4" e2="DDI-PubMed.24820076.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e4" e2="DDI-PubMed.24820076.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e4" e2="DDI-PubMed.24820076.s5.e6" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e5" e2="DDI-PubMed.24820076.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24820076.s5.e5" e2="DDI-PubMed.24820076.s5.e6" /></sentence><sentence text=" Time- and concentration-dependent kinetics of inhibition by the antituberculosis drugs were determined using genotyped human liver microsomes (HLMs) and recombinant CYP2A6, CYP2B6" /><sentence text="1, and CYP2B6" /><sentence text="6 enzymes" /><sentence text=" Although none of the antituberculosis drugs evaluated at up to 10 times clinical plasma concentrations were found to inhibit efavirenz 8-hydroxylation by HLMs, both rifampin (apparent inhibition constant [Ki] = 368 μM) and pyrazinamide (Ki = 637 μM) showed relatively weak inhibition of efavirenz 7-hydroxylation"><entity charOffset="126-135" id="DDI-PubMed.24820076.s9.e0" text="efavirenz" /><entity charOffset="166-174" id="DDI-PubMed.24820076.s9.e1" text="rifampin" /><entity charOffset="224-236" id="DDI-PubMed.24820076.s9.e2" text="pyrazinamide" /><entity charOffset="288-297" id="DDI-PubMed.24820076.s9.e3" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e0" e2="DDI-PubMed.24820076.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e0" e2="DDI-PubMed.24820076.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e0" e2="DDI-PubMed.24820076.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e0" e2="DDI-PubMed.24820076.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e1" e2="DDI-PubMed.24820076.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e1" e2="DDI-PubMed.24820076.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e1" e2="DDI-PubMed.24820076.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e2" e2="DDI-PubMed.24820076.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24820076.s9.e2" e2="DDI-PubMed.24820076.s9.e3" /></sentence><sentence text=" Importantly, isoniazid demonstrated potent time-dependent inhibition of efavirenz 7-hydroxylation in both HLMs (inhibitor concentration required for half-maximal inactivation [KI] = 30 μM; maximal rate constant of inactivation [kinact] = 0"><entity charOffset="14-23" id="DDI-PubMed.24820076.s10.e0" text="isoniazid" /><entity charOffset="73-82" id="DDI-PubMed.24820076.s10.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.24820076.s10.e0" e2="DDI-PubMed.24820076.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24820076.s10.e0" e2="DDI-PubMed.24820076.s10.e1" /></sentence><sentence text="023 min(-1)) and recombinant CYP2A6 (KI = 15 μM; kinact = 0" /><sentence text="024 min(-1)) and also formed a metabolite intermediate complex consistent with mechanism-based inhibition" /><sentence text=" Selective inhibition of the CYP2B6" /><sentence text="6 allozyme could not be demonstrated for any of the antituberculosis drugs using either recombinant enzymes or CYP2B6*6 genotype HLMs" /><sentence text=" In conclusion, the results of this study identify isoniazid as the most likely perpetrator of this clinically important drug-drug interaction through mechanism-based inactivation of CYP2A6"><entity charOffset="51-60" id="DDI-PubMed.24820076.s15.e0" text="isoniazid" /></sentence><sentence text=" " /></document>